Company News: Pfizer

Share this article:
Pfizer said it will supply its Prevnar 13 pediatric vaccine to impoverished countries for 10 years under the terms of a UNICEF pilot project aimed at fighting pneumococcal disease, the leading cause of vaccine-preventable death for children under 5 globally. Under the terms of an Advance Market Committment agreement, Pfizer has agreed to charge no more than $3.50 per dose for 10 years to meet long-term demand and ensure affordability of the vaccine in developing countries even after the donor contributions are exhausted.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies